Podcast: Curare grazie al silenziamento dei geni, con Dicerna

Seleziona il tuo profilo per continuare sul nostro sito

Per favore, leggi le importanti informazioni riportate di seguito prima di continuare sul nostro sito

Lyxor e Lyxor ETF sono nomi utilizzati da Société Générale per identificare rispettivamente le società di Asset Management Lyxor e i prodotti da loro emessi, promossi e/o gestiti.

Société Générale è un istituto di credito di diritto francese autorizzato e controllato in Francia dall’ Autorité de Controle Prudentiel (www.acp.banque-france.fr ), oltre che dall’ Autorité des Marchés Financiers. Société Générale è autorizzata ad operare in qualità di istituto di credito ed abilitata ad effettuare tutte le operazioni bancarie, nonché abilitata alla prestazione di tutti i servizi d’investimento ad eccezione del servizio di gestione di Sistema Multilaterale di negoziazione, ai sensi delle disposizioni del Code Monétaire et Financier.

Société Générale opera in Italia attraverso la succursale di Milano, con domicilio in Via Olona 2, 20123 Milano, Italia. Per informazioni relative a questo sito web: Numero Verde 800 929300 Email: info@etf.it

I Lyxor ETFs presentati sul sito www.ETF.it potrebbero essere soggetti a restrizioni per quanto riguarda certe persone o in certi paesi in base alla legislazione locale applicabile alle suddette persone o nei suddetti paesi. E’ responsabilità del cliente assicurarsi di essere autorizzato ad investire nei Lyxor ETFs presentati in questo sito.

Gli investitori UK devono fare riferimento a www.lyxoretf.co.uk

Gli investitori Francesi devono fare riferimento a www.lyxoretf.fr

Gli investitori Olandesi devono fare riferimento a www.lyxoretf.nl

Gli investitori Italiani devono fare riferimento a www.lyxoretf.it

Gli investitori Spagnoli devono fare riferimento a www.lyxoretf.es

Gli investitori Austriaci devono fare riferimento a www.lyxoretf.at

Gli investitori Tedeschi devono fare riferimento a www.lyxoretf.de

Gli investitori di Hong Kong devono fare riferimento a www.lyxoretf.hk

Gli investitori Singaporesi devono fare riferimento a www.lyxoretf.sg

Gli investitori Svizzeri devono fare riferimento a www.lyxoretf.ch

Gli investitori Belgi devono fare riferimento a www.lyxoretf.be

I Lyxor ETFs a cui si fa riferimento in questo sito non sono stati e non saranno registrati sotto il United States Securities Act del 1933 e successive modifiche, e non potranno essere offerti o venduti entro i confini degli Stati Uniti, ad eccezione dei casi di esenzione previsti dal Securities Act, o se nel contesto di una transazione non soggetta agli obblighi di registrazione del Securities Act. Quindi, gli ETF elencati in questo sito internet non potranno essere venduti a cittadini statunitensi o comunque non potranno essere altrimenti trasferiti negli Stati Uniti salvo il caso in cui la transazione di riferimento non sia soggetta ad obblighi di registrazione ai sensi della legge americana.

Coloro i quali accedono al sito internet da una giurisdizione nella quale sono vigenti delle restrizioni, dovrebbero informarsi a riguardo, e osservare tali restrizioni.

Il presente sito internet non costituisce un offerta o un invito ad acquistare titoli negli Stati Uniti o in qualunque altra giurisdizione in cui simili offerte o inviti non siano autorizzati o a qualunque persona nei confronti della quale sia illegale fare tale offerta o invito. I potenziali utenti del presente sito internet sono invitati a informarsi ed ad osservare tali restrizioni.

Questo sito internet ha natura commerciale e non regolamentare. L’accuratezza, la completezza o la rilevanza delle informazioni fornite non è garantita, benchè tali informazioni siano state ricavate da fonti ritenute attendibili. Le informazioni presentate in questo sito internet si basano su dati di mercato in un determinato momento e potrebbero cambiare nel tempo.

I Lyxor ETFs descritti nel presente sito non sono adeguati a ogni investiture. L’investitore può perdere fino alla totalità del capitale investito. L’investitore non dovrebbe investire in questi prodotti salvo che ne comprenda pienamente le caratteristiche e il livello di esposizione al rischio. Il valore dei Lyxor ETFs può essere soggetto ad incrementi e riduzioni ed è soggetto a volatilità dovuta a fattori quali variazioni di prezzo degli strumenti sottostanti e dei tassi di interesse. Se il Lyxor ETF è denominato in una valuta diversa dall’indice, è soggetto ad un rischio di cambio.

Prima di ogni investimento in un Lyxor ETF, l’investitore dovrebbe fare la propria valutazione dei rischi dell’investimento sotto il profilo legale, fiscale e contabile, senza fare riferimento alle informazioni fornite in questo sito internet, rivolgendosi, se lo riterrà opportuno, ai propri consulenti specializzati o ad altri professionisti competenti .

Nessuna entità del gruppo Société Générale, potrà essere ritenuta responsabile per le conseguenze finanziarie o di altra natura che potrebbero derivare dall’investimento nei Lxyor ETFs.

Prima di ogni eventuale investimento nei Lyxor ETFs si raccomanda di leggere attentamente i Prospetti, i KIID e i Documenti di Quotazione, disponibili sul presente sito e presso Société Générale, Listed Products, via Olona 2, 20123 Milano, in cui sono illustrati in dettaglio i relativi meccanismi di funzionamento, i fattori di rischio ed i costi.

A private investor is a self directed retail client who is making investment decisions on their own behalf in their personal stock broking account, Self Invested Personal Pension or individual savings account

A financial Adviser is a qualified investment professional who provides financial advice or guidance to investors based on their own personal financial situation and risk profile

A professional client is a client that is either a per se professional client or an elective professional client (Note article 4 (1) 12 of Mifid ):

An entity required to be authorised or regulated to operate in the financial markets. The following list includes all authorised entities carrying out the characteristic activities of the entities mentioned, whether authorised by an EEA State or a third country and whether or not authorised by reference to a directive:
- a credit institution
- an investment firm
- any other authorised or regulated financial institution
- an insurance company
- a collective investment scheme or the management company of such a scheme
- a pension fund or the management company of a pension fund
- a commodity or commodity derivatives dealer
- a local
- any other institutional investor
In relation to MiFID or equivalent third country business, a large undertaking, meeting two of the following size requirements on a company basis:
- balance sheet total of EUR 20,000,000
- net turnover of EUR 40,000,000
- own funds of EUR 2,000,000
In relation to business that is neither MiFID or equivalent third country business, a large undertaking meeting either of the following conditions:
- a body corporate (including a limited liability partnership) which has (or any of whose holding companies or subsidiaries has) called up share capital of at least £10 million (or its equivalent in any other currency at the relevant time)
- a large undertaking that meets (or any of whose holding companies or subsidiaries meets) two of the following tests: (i) a balance sheet total of EUR 12,500,000; (ii) a net turnover of EUR 25,000,000; (iii) an average number of employees during the year of 250
- a national or regional government, a public body that manages public debt, a central bank, an international or supranational institution (such as the World Bank, the IMF, the ECP, the EIB) or another similar international organisation.
- another institutional investor whose main activity is to invest in financial instruments (in relation to the firm's MiFID or equivalent third country business) or designated investments (in relation to the firm's other business). This includes entities dedicated to the securitisation of assets or other financing transactions

The above definition is only an extract and is not exhaustive. For further details please refer to the Glossary section of the FSA Handbook: https://www.handbook.fca.org.uk/handbook/glossary/

The information on this website is published by Lyxor Asset Management UK LLP (Lyxor UK), a member of the Société Générale group of companies ("Lyxor UK Group"). Lyxor UK is authorized by Financial Conduct Authority in the UK, under FCA Registration Number 435658.

You should note that an investment in any of these Exchange Traded Funds will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme.

Although information contained herein is from sources believed to be reliable, Lyxor UK makes no representation or warranty regarding the accuracy of any information. Any reproduction, disclosure or dissemination of these materials is prohibited. This site is maintained by Lyxor UK, 1 Bank Street, Canary Wharf, London, E14 4SG.

GENERAL GUIDANCE

Lyxor UK is the promoter of Lyxor UK Exchange Traded Funds. You cannot trade directly with Lyxor UK.

A number of technical terms are used on this website. If you are in any doubt as to the meaning of such terms, then you should first consult Academy section. There is also a FAQ function which explains some of the terms contained in the website. If you require further clarification please do not hesitate to contact us directly on info@lyxoretf.co.uk, or call 0800 707 6956.

INVESTMENT RISKS

The Lyxor UCITS ETFs described on this website are not suitable for everyone. Investors capital is at risk. Investors should not deal in this product unless they understand, having obtained independent professional advice where necessary, its nature, terms and conditions, and the extent of their exposure to risk. The value of the product can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. If a fund is quoted in a different currency to the index, currency risks exist. Prior to any investment in any Lyxor UCITS ETF, you should make your own appraisal of the risks from a financial, legal and tax perspective, without relying exclusively on the information provided by us. We recommend that you consult your own independent professional advisors (including legal, tax, financial or accounting advisors, as appropriate)

SPECIFIC RISKS

Counterparty risk: Through Lyxor UCITS ETFs, investors are exposed to counterparty risk resulting from the use of OTC swaps with Société Générale. Pursuant to the UCITS Directive 2009/65/EC (as may be amended), the exposure of a UCITS to a swap counterparty which is a credit institution for the purpose of the Directive, cannot exceed 10% of the total fund assets. It is recommended that potential investors study the fund prospectus before investing.

As of March 2020, the long term, senior, unsecured debt obligations of Société Générale were rated A by Standard and Poor’s Ratings Services (S & P) and A2 by Moody’s Investor’s Services Inc (Moody’s). Companies are rated by S&P from AAA (highest rating / most secure) to D (lowest rating / in default / most risky), and by Moody’s from Aaa (highest rating / most secure) to C (lowest rating / in default / most risky).

Liquidity risk: Société Générale is not the only market-maker for Lyxor UCITS ETFs. Société Générale and any other market makers supporting Lyxor UCITS ETFs on exchange must follow the respective London Stock Exchange (LSE) requirements and guidelines. On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the index tracked by the ETF; a failure in the LSE, Société Générale or other market-maker systems; or an abnormal trading situation or event.

PRODUCT SPECIFIC RISK FACTORS

Capital at Risk ETFs are tracking instruments: Their risk profile is similar to a direct investment in the Benchmark Index. Investors’ capital is fully at risk and investors may not get back the amount originally invested. Investments are not covered by the provisions of the Financial Services Compensation Scheme ("FSCS"), or any similar scheme.

Counterparty Risk Investors may be exposed to risks resulting from the use of an OTC (over the counter) Swap with Lyxor UK. Physical ETFs may have Counterparty Risk resulting from the use of a Securities Lending Programme.

Currency Risk ETFs may be exposed to currency risk if the ETF or Benchmark Index holdings are denominated in a currency different to that of the Benchmark Index they are tracking. This means that exchange rate fluctuations could have a negative or positive effect on returns

Replication Risk ETFs are designed to replicate the performance of the Benchmark Index. Unexpected events relating to the constituents of the Benchmark Index may impact the Index provider’s ability to calculate the Benchmark Index, which may effect the ETF’s ability to replicate the Benchmark Index efficiently. This may create Tracking Error in the ETF.

The Benchmark Index of a Lyxor ETF may be complex and volatile. When investing in commodities, the Benchmark Index is calculated with reference to commodity futures contracts which can expose investors to risks related to the cost of carry and transportation. ETFs exposed to Emerging Markets carry a greater risk of potential loss than investment in Developed Markets as they are exposed to a wide range of unpredictable Emerging Market risks.

Liquidity Risk On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the Benchmark Index tracked by the ETF; a failure in the systems of one of the relevant stock exchanges, Lyxor UK or other Market Maker systems; or an abnormal trading situation or event.

The Sub-Funds are recognised Collective Investment Schemes for the purposes of Section 264 of the Financial Services and Markets Act 2000 (the "FSMA") and the Prospectus is available to the general public in the United Kingdom on this website. You are advised that most, if not all, of the protections provided by the United Kingdom regulatory system generally and for UK authorised funds do not apply to recognised funds such as these Sub-Funds

The information on this website is published in the UK by Lyxor Asset Management UK LLP (Lyxor UK), which is authorized by the Financial Conduct Authority in the UK, under FCA Registration Number 435658.

The website is hosted by on Microsoft Azure servers.

This website is subject to French law and English Law

Lyxor and Lyxor ETF are names used by Lyxor Asset Management UK LLP to promote the products of Lyxor International Asset Management. Although information contained herein is from sources believed to be reliable, Lyxor Asset Management UK LLP makes no representation or warranty regarding the accuracy of any information. Any reproduction, disclosure or dissemination of these materials is prohibited.

This website is published by Lyxor International Asset Management (LIAM), a simplified joint stock company (société par actions simplifiée) with capital of 1,059,696 euros, listed on the Nanterre Trade and Companies Register under the single identification number 419,223,375 and EPA number 6630Z.

Registered office: Tours Société Générale, 17 cours Valmy, 92800 Puteaux.

Intra-community VAT number: FR 50419223375
Legal representative and director of publication: Lionel Paquin, Chairman, Lyxor International Asset Management.

Managing editor: Nathalie Boschat, Head of the Lyxor Communications Department (Tel.: +33 1 42 14 83 21); e-mail: Nathalie.Boschat@sgcib.com).

This website is hosted on Microsoft Azure servers.
This website is subject to French law.

Professional regulation

LIAM is a French asset management company approved by the AMF (17 place de la Bourse 75082 Paris Cedex 02) under the UCITS (2009/65/EC) and AIFM (2011/31/EU) directives.

Site content

LIAM endeavors to ensure the accuracy and updating of information on this website, and reserves the right to modify the content at any time without notice. LIAM cannot however guarantee its completeness or the absence of modification by a third party (intrusion, virus). Moreover, LIAM accepts no liability in case of difficulty or inability to access the website due to an internet connection problem.

As such, LIAM does not accept liability for any consequential damages such as, but not limited to, losses arising from transactions made on the basis of the information, loss of profit, loss of business, loss resulting from an interruption of service, increased costs of access and information processing.

Similarly, LIAM cannot be held liable for factors beyond its control or any damage that may be suffered by your technical environment, including your computers, software, network equipment (modems, phones, etc.) and any equipment used to access or use the service and/or information.

Finally, LIAM cannot guarantee, and accepts no liability as regards the sequence, accuracy, absence of errors, veracity, currency, merchantability, quality, correctness or non-infringing character and availability of the information on this website.

You undertake to use the information contained on this website for personal, non-commercial purposes.

Information on products and services

The products and services offered by LIAM are not available in all jurisdictions, notably due to regulatory constraints. The terms and conditions relative to products and services (if any) are indicative. The information regarding products and services does not constitute on the part of LIAM or any of its affiliates either an offer to buy, sell or subscribe for financial products or services, or the solicitation of an offer to buy or sell.

LIAM assumes no liability for the accuracy, completeness or adequacy of the information derived from external sources, although the information is obtained from sources deemed reliable.

WHEN PAST PERFORMANCE OR SIMULATED PAST PERFORMANCE IS PRESENTED, THE DATA RELATED THERETO REFER TO PAST PERIODS, AND ARE NOT RELIABLE INDICATORS OF FUTURE RESULTS. THE SAME APPLIES TO VARIATIONS IN HISTORICAL MARKET DATA.

When simulations of future performance are presented, the data relative to these performances are only predictions, and are not a reliable indicator of the future performance of the product. Moreover, where past performance or simulated past performance are based on data expressed in a currency that is not that of the state of residence of the investor, potential gains may increase or decrease based on changes in exchange rates. Finally, where past performance or simulated performances (past or future) are presented, any gains can also be reduced by the effect of commissions, fees or other charges borne by the investor.

Anyone wishing to obtain any of the services or products presented on this website is requested to contact LIAM to inquire about the availability of the service or product in question, and the contractual terms and rates applicable to it.

Subscription of products and services

As part of its legal and regulatory obligations (including those resulting from the European directive on Markets in Financial Instruments – MIFiD), LIAM may be required, depending on the type of products it offers and the classification it assigns you, to verify the suitability or appropriateness of the financial instruments in relation to your hedging or investment objectives, your knowledge and your experience.

Without prejudice to the legal or regulatory obligations borne by LIAM, investors should, before investing in the product or concluding any transaction relating thereto, conduct their own analysis of the product and its risks, especially in respect of legal, tax and accounting aspects, without relying solely on information provided to them. Investors should consult, if they deem it necessary, their own advisors or any other professional on this matter. Subject to compliance with its legal and regulatory requirements, LIAM shall not be held liable for the financial consequences of any nature whatsoever arising from any transaction relating to the product or any investment in the product.

Any online application for subscription to a product or service offered by LIAM is only valid after acceptance by it, and involves the submission of the transaction to contractual and tariff conditions, as well as to French law.

Intellectual property

The entire website is covered by French and international copyright, trademark and, more generally, intellectual property law, both in terms of its form (choice, plan, layout of materials, means of access to data, organization of data, etc.), and in respect of each element of its content (text, images, etc.). The content appearing on the pages of this website is the exclusive property of LIAM. You further undertake not to use such content and not to allow anyone else to use this content for illegal purposes.

Exceptionally, some content (text, images) may be the property of its respective authors.

Any reproduction, distribution or redistribution in whole or in part of the content of this website in any form or by any means whatsoever (including by caching or framing), or any sale, resale, retransmission or distribution to third parties in any way whatsoever is prohibited. Failure to comply with this prohibition constitutes an infringement that may result in civil and criminal penalties.

The hypertext links to other websites do not engage the liability of LIAM, particularly as regards the content of these websites.

LIAM is not responsible for hypertext links pointing to this website, and prohibits any person from establishing such a link without its express consent.

Marketing Restrictions and Implications

Lyxor UCITS compliant Exchange Traded Funds (Lyxor UCITS ETFs) referred to on this website are open ended mutual investment funds (i) established under the French law and approved by the Autorité des Marchés Financiers (the French Financial Markets Authority), or (ii) established under the Luxembourg law and approved by the Commission de Surveillance du Secteur Financier (the Luxembourg Financial Supervisory Committee). Most, if not all, of the protections provided by theUK regulatory system generally and for UK authorised funds do not apply to these exchange traded funds (ETFs). In particular, investors should note that holdings in this product will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme in France.

This website is exclusively intended for persons who are not "US persons", as such term is defined in Regulation S or the US Securities Act 1933, as amended, and who are not physically present in the US. This website does not constitute an offer or an invitation to purchase any securities in the United States or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this website are requested to inform themselves about and to observe any such restrictions.

Index Replication Process

Lyxor UCITS ETFs follow both physical and synthetic index replication process.

However, most Lyxor UCITS ETFs follow synthetic replication process. This consists of entering into a derivative transaction (a ‘Performance Swap’, as defined below) with a counterparty that provides complete and effective exposure to its benchmark index. Lyxor has adopted this methodology in order to minimise tracking error, optimise transaction costs and reduce operational risks.

A Performance Swap is a contractual agreement which is negotiated over-the-counter (OTC) between two parties: the Lyxor UCITS ETF and its counterparty. From a risk perspective, each Performance Swap ranks equally with other senior unsecured obligations of the counterparty, such as common bonds (i.e., same rights to payments). In the Performance Swap, the counterparty of the Lyxor UCITS ETF commits to pay the Lyxor UCITS ETF a variable return based on a pre-determined benchmark index, instead of a fixed stream of income (as in bonds). At the same time, the counterparty will receive from the Lyxor UCITS ETF the performance and any related revenues generated by the basket's assets (excluding the value of the Performance Swap) held by the Lyxor UCITS ETF. Information provided on individual ETFs includes data on the basket relating to the ETF and the percentage value of the basket represented by each asset. The information is relevant to the closing values on the date given.

Tax

Any statement in relation to tax, where made, is generic and non-exhaustive and is based on our understanding of the laws and practice in force as of the date of this document and is subject to any changes in law and practice and the interpretation and application thereof, which changes could be made with retroactive effect. Any such statement must not be construed as tax advice and must not be relied upon. The tax treatment of investments will, inter alia, depend on an individual’s circumstances. Investors must consult with an appropriate professional tax adviser to ascertain for themselves the taxation consequences of acquiring, holding and/or disposing of any investments mentioned on this website.

Any fund prospectus and supplements are available at www.lyxoretf.co.uk. Information given about the past performance of the funds is no guarantee of future performance. No investment decision should be taken without reading the fund prospectus and the key information document available of the fund concerned.

Although the content of the website is based upon information that Lyxor UK consider reliable or comes from sources that Lyxor UK consider reliable, Lyxor UK has not verified such information. Lyxor UK make no representation or warranty as to the accuracy, completeness or adequacy of any information. Any reproduction, disclosure or dissemination of the materials available on the website is prohibited.

This document has been edited with the free version of the instant HTML edior. Try it here and use it every time for your projects.

IMPORTANT INFORMATION

Any third-party advertising, information and referral buttons containing hyperlinks are not recommendations or endorsements by Lyxor UK or its respective directors, affiliates or employees. The user is referred to the relevant third party for all relevant information, including complete information on that entitys investment adviser or dealer licensing status (if applicable).

All reasonable care has been taken by Lyxor UK to ensure that all statements of fact and opinion contained in the materials provided by a third party are fair, clear and not misleading. Nevertheless, Lyxor UK makes no representation or warranty regarding the accuracy of any third party information and is not responsible for third party content in any way.

UK residents only. This site is intended for Professional Clients who intend to trade in Lyxor UK Exchange Traded Funds in the United Kingdom. It is not provided to any person who is a resident of any other country.

You should note that holdings in this product will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme. In particular, the investments can be neither offered nor transferred in the United States.

No investment advice Nothing in this website constitutes advice on the merits of buying, or selling a particular investment or exercising any right conferred by the products described. Lyxor UK does not offer investment advice in respect of these products. Unless you are an institutional or professional investor, you should seek independent financial advice in relation to the products contained in this website.

Accuracy and reliability of information The information in this website is, to Lyxor UKs knowledge, reliable and accurate but this cannot be guaranteed. The views of Lyxor UK reflected in this website may change without notice. Figures included in this website take no account of personal tax liability.

No investment decision should be taken without reading the Legal Documents relating to the particular Exchange Traded Fund concerned. A copy of the Legal Documents may be obtained from Lyxor UK at SG House, 1 Bank Street, Canary Wharf, London, E14 4SG upon request.

Disclosure of interest Lyxor UK or its associates may from time to time have a position, or material interest in the products described in this website or the investments underlying them.

Generally Lyxor UK will be the only market maker in the Exchange Traded Funds discussed and will or may have provided significant advice in relation to the Exchange Traded Funds and the investments underlying them.

This is the privacy and cookies policy for the Lyxor ETF website, which is operated by Lyxor Asset Management UK LLP (Lyxor UK).

Collection of your information

Lyxor UK may obtain personal information about you during the course of your participation with the Lyxor ETF website, sometimes through the use of on-line or off-line forms.

Use of your information

The information you voluntarily provide us through this website or email (which may include your name, company, address and contact details such as your telephone number, email address or fax number) will be used for the following purposes:

to send you information and updates about products on the Lyxor ETF website;
to satisfy your requests, such as publications or information relating to Lyxor ETF;
to respond to your query if you have emailed us with an enquiry (for example, in relation to any Lyxor ETF or a forthcoming publication or event);
to send you further information and marketing materials about our services, products, publications, events or keep you informed through our periodic newsletters provided that you have indicated that you are happy to be contacted for these purposes.

Who do we share your information with?

We may (to the extent necessary) pass your personal information to members of the Societe Generale Group and Lyxor UK’s partners, providers, and subcontractors (for whom we remain responsible in this regard) who assist us in providing the services we offer, such as fulfilling requests for information, receiving and sending communications, updating marketing lists, analysing data, providing support services or in other tasks from time to time. Our agents and contractors will only use your information to the extent necessary to perform their functions.

In the event that we undergo re-organisation or are sold to a third party, you agree that any personal information we hold about you may be transferred to that re-organised entity or third party.

We may disclose personal information about you if required to do so by law enforcement or other government or regulatory bodies and their officials or to third parties in connection with an investigation of fraud, intellectual property infringement, breach of any law or other activity that is illegal or which may expose us to legal liability, or in order to protect our rights and property.

International Transfers

Your personal data may be processed by staff operating outside the European Economic Area ("EEA") or your local jurisdiction who work for us or for one of our suppliers chosen for their expertise in certain areas. This may, for example, happen if one or more of our servers are from time to time located in a country outside the EEA or one of our service providers is located in a country outside the EEA. If we transfer your information outside the EEA in this way, we will take steps to ensure that your privacy rights continue to be protected

What are Cookies and how are they used?

This policy explains how our website uses Cookies. It forms part of the important information and the terms and conditions of our website.

A cookie is a small file, typically of letters and numbers, downloaded on to a device when the user accesses certain websites. Cookies allow this website to recognise your computer throughout your session.

The Lyxor ETF website uses a combination of the types of cookies listed below:

What cookies do we use?	What is the purpose of the Cookie?	What is the shelf life?
JSESSIONID	These cookies are used to customise the visitor experience and save the user preferences by linking it to the website account.	Session
_ga	This cookie name is asssociated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguishes unique users by assigning a randomly generated number as a client identifier.	2 Years
_gat	This cookie name is associated with Google Universal Analytics, according to documentation it is used to throttle the request rate - limiting the collection of data on high traffic sites.	10 minutes
disclaimerinstit	These cookies are used to remember if the visitor has accepted the disclaimer for institutional profile	1 Month

How do I set my cookie preferences?

Most web browsers allow some control of most cookies through the browser settings.

You may also delete and block all cookies from the Lyxor ETF Website but parts of the Lyxor ETF website may not work.

To find out more about cookies, including how to see what cookies have been set and how to manage and delete them, visit www.aboutcookies.org or www.allaboutcookies.org.

Other websites

The Lyxor ETF website may, from time to time, contain links to and from the websites of our partners, advertisers or other websites providing relevant information. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

Your rights of access and rights to modify your personal information

You have the right to ask for a copy of the personal information we hold about you in our records by writing to Lyxor ETF, SG House, 1 Bank Street, Canary Wharf, London, E14 4SG. Alternatively, you can email info@lyxoretf.co.uk.

You also have the right, at any time, to object to the processing of your personal information, to require us to correct any inaccuracies in your information or to remove such information or to request us not to process your personal data for marketing purposes.

You should contact us at the above address if you wish to do any of these things. We will retain in our files certain information you have requested us to remove in order to resolve future disputes, to troubleshoot problems or to enforce the Terms. We will retain data only for the duration of the purpose for which it was obtained and may need to retain some details about you after your relationship with Lyxor UK has ended, for example for legal and regulatory purposes.

What to do if you wish to stop hearing from us

If you no longer wish to hear from Lyxor ETF about opportunities or if any of your details change, please inform us by email at info@lyxoretf.co.uk.

Changes to our privacy policy Ancre

Any changes we may make to our privacy policy in the future will be posted on this page and, where appropriate, may be notified to you by e-mail.

27 set 2021

Podcast: Curare grazie al silenziamento dei geni, con Dicerna Pharmaceuticals

Nell'ultima puntata del nostro podcast One Step Ahead, pensato per aiutarti a preparare il tuo portafoglio alle sfide del futuro, puntiamo i riflettori su Dicerna Pharmaceuticals, una società innovatrice nel campo della medicina genetica nonché una delle società presenti nel nostro ETF Disruptive Technology.

Dicerna Pharmaceuticals è una società biofarmaceutica del Massachusetts specializzata nell'interferenza a RNA (iRNA), una tecnologia rivoluzionaria che permette di individuare e inibire certi geni patogeni per ripristinare la salute dei pazienti e migliorare la loro qualità di vita.

Per comprendere l'iRNA e scoprire cosa ci riserva il futuro della medicina basata sui geni, abbiamo parlato con il dottor Douglas Fambrough, Ph.D., CEO e Presidente di Dicerna. Che si tratti di malattie renali, disturbi neurologici o perfino disturbi legati al consumo di alcol, il dottor Fambrough sostiene che i farmaci basati sui geni potrebbero diventare un approccio sicuro ed efficace per trattare le malattie. Secondo Fambrough, ci troviamo agli inizi di una fase rivoluzionaria per la medicina basata sui geni e l'iRNA è solo una delle tante tecnologie dirompenti destinate a cambiare il futuro della sanità.

Diana

Douglas Fambrough
Presidente e CEO,

Dicerna Pharmaceuticals

Di seguito riportiamo alcuni punti salienti dell'episodio. Potete ascoltare l'intero episodio sulla vostra piattaforma preferita (Spotify, Apple Podcasts, Google Podcasts, Stitcher) o direttamente dal sito web di Lyxor ETF:

Libby: Douglas, l'espressione "we interfere" (noi interferiamo) ricorre spesso sul sito web di Dicerna. Potrebbe spiegare ai nostri ascoltatori il suo significato?

Douglas: Con piacere. Abbiamo cercato una frase ad effetto e un po' insolita, che catturasse l'attenzione. A Dicerna, interferiamo con la malattia. Le malattie sconvolgono profondamente la vita delle persone e noi vogliamo interferire con la loro capacità di farlo.

L'espressione è un gioco di parole che richiama il nome della tecnologia che utilizziamo, l'interferenza a RNA, ma serve soprattutto ad attirare l'attenzione e a spiegare che "interferiamo" con la malattia per cercare di far guarire i pazienti.

Libby: Sulle innovazioni in campo genomico e sanitario sono stati versati fiumi di inchiostro e termini quali mRNA, terapia genica ed editing genomico sono comparsi sulle prime pagine di tutti i giornali, soprattutto in relazione ai vaccini contro il Covid-19. Potrebbe illustrarci brevemente le differenze tra questi concetti e spiegarci cosa distingue l'approccio di Dicerna in fatto di silenziamento dei geni?

Douglas: Conosciamo tutti, credo, il macchinario che ogni giorno fa funzionare il nostro corpo. È costituito principalmente da proteine. (...) Ma abbiamo anche un codice genetico, un "insieme di istruzioni", che codifica tutte le informazioni necessarie per fabbricare queste proteine. Il nostro genoma, questo insieme di istruzioni genetiche, può essere paragonato ad un voluminoso ricettario di 20-30 mila pagine, ciascuna delle quali contenente la ricetta per costruire una specifica proteina.

Se ci pensate, portare sul tavolo da cucina un libro così ingombrante, in cui ogni proteina corrisponde ad un piatto preparato, è impossibile. Per fabbricare la proteina occorrerà pertanto fare una copia della pagina che ci interessa e portarla sul piano di lavoro. Tradizionalmente i farmaci erano concepiti per interferire con il macchinario, interagendo con le proteine che vengono fabbricate.

Tutte le tecnologie che ha menzionato, invece, si interessano all'insieme di istruzioni genetiche e si concentrano sul grosso ricettario o sulla copia di una particolare pagina. (…)

L'mRNA è la copia di una pagina del ricettario del genoma che è fatta per codificare una proteina specifica. Le società specializzate nell'mRNA si occupano di fornire una copia dall'esterno. Nel caso dei vaccini, forniscono una copia della proteina virale che il nostro organismo poi trasforma nella proteina virale in modo che il nostro sistema immunitario possa riconoscerla. Non è infettiva, perché non abbiamo a che fare con il virus completo, ma si tratta di un meccanismo efficace quando al paziente manca un gene. Permette infatti di rimettere la copia del gene mancante nell'organismo affinché la proteina possa essere fabbricata. Oppure se c'è bisogno che un gene sia più attivo o se c'è carenza di un particolare ormone ecc., è possibile inserirne una copia nell'organismo e produrre maggiori quantità di quell'ormone.
Noi facciamo l'opposto. Se un paziente presenta una quantità eccessiva di un particolare gene, la tecnologia dell'interferenza a RNA ostacola la capacità di leggere la copia del gene. Questo meccanismo viene talvolta chiamato silenziamento genico, in quanto impedisce che il gene si trasformi in proteina. Numerose malattie comuni (cardiovascolari, gastriche, autoimmuni, infiammatore,) implicano la presenza di un processo biologico eccessivo. (…)

Le altre tecnologie che ha menzionato (terapia genica, editing genomico) agiscono sull'insieme di istruzioni stesso. L'insieme di istruzioni è permanente, mentre le copie sono provvisorie. Pertanto, quando si interviene a livello di copie, con l'mRNA o l'interferenza a RNA, l'effetto dura per un po', quindi viene meno e occorre somministrare nuovamente il farmaco. Le tecnologie che lavorano sul set di istruzioni, invece, sono permanenti e durano tutta la vita, ragion per cui bisogna stare molto attenti.

La terapia genica, come viene comunemente chiamata, consiste sostanzialmente nell'inserire una nuova pagina nel genoma. Di conseguenza, se una delle pagine manca o viene danneggiata e smette di funzionare correttamente, è possibile inserire una nuova pagina e una pagina supplementare a sostituzione di quella difettosa. Si tratta di un approccio particolarmente efficace per le malattie genetiche, quando manca un gene o una persona eredita una copia difettosa di un gene da entrambi i genitori. (…)
L'ultima tecnologia, quella più recente e per la quale al momento non vi sono ancora prodotti approvati a differenza delle altre tre, è l'editing genomico. Si tratta di un meccanismo che permette di entrare nelle singole pagine e modificare letteralmente le parole. Un semplice metodo di modifica consiste nel cancellare delle cose, o ad esempio prendere una pagina e distruggerla. È un po' come l'interferenza a RNA, nel senso che si disattiva il gene rompendolo a livello dell'insieme di istruzioni. E l'effetto è permanente. (…) Un altro modo per farlo, leggermente più complicato e ad uno stadio più precoce del processo di sviluppo tecnologico, consiste nel correggere un errore. Si prende una pagina scritta in modo non corretto e si corregge il codice. (…)

Libby: Cosa può dirci del potenziale di Dicerna a trattare patologie diverse da quelle a carico del fegato?

Douglas: Per una serie di ragioni, il fegato è il tessuto più efficace da trattare con l'interferenza a RNA. Ma avendo capito come far funzionare e ottimizzare questo meccanismo nel fegato abbiamo appreso come potremmo modificare e affinare la tecnologia in modo da applicarla ad altri tessuti dell'organismo, come il tessuto polmonare, il tessuto adiposo nonché tessuti o cellule che fanno parte del sistema immunitario. E questo apre la strada ad un'enorme varietà di applicazioni.

Inoltre, se si tiene conto delle applicazioni al sistema nervoso centrale per patologie come il dolore cronico o malattie neurodegenerative quali l'Alzheimer o il Parkinson, le applicazioni della tecnologia sono decisamente troppo numerose per Dicerna da sola.

Per entrare in queste altre aree terapeutiche, alcune delle quali sono estremamente vaste ed esulano dalla nostra capacità, collaboriamo con società come Roche, Eli Lilly e Novo Nordisk. Per esempio, stiamo lavorando con Roche, una grande multinazionale di portata globale, per sviluppare un programma di trattamento del virus dell'epatite B, che colpisce centinaia di milioni di pazienti in tutto il mondo.

Segui il resto della conversazione collegandoti alla puntata integrale su One Step Ahead.

Il podcast contiene dichiarazioni previsionali e i risultati effettivi potrebbero essere sostanzialmente diversi; ti invitiamo a visionare i "Fattori di rischio" tra gli ultimi SEC Filings di Dicerna.

Gli ETF in evidenza

Al momento della registrazione di questo podcast, Dicerna Pharmaceuticals era un titolo detenuto all’interno di Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF (ticker Bloomberg: UNIC), conforme all’articolo 8 della normativa SFDR.

Anche il gigante svizzero del settore farmaceutico Roche, con cui Dicerna ha collaborato a una terapia RNAi per il trattamento del virus dell'epatite B, è un titolo presente nel nostro ETF Disruptive Technology.

Scopri di piu sui nostri ETF Tematici

Questo podcast è a mero scopo informativo e non deve essere considerato come un consiglio di investimento e/o un'offerta di acquisto di prodotti finanziari. Lyxor International Asset Management, proprietaria del marchio Lyxor ETF, non sostiene o promuove in alcun modo alcuna società o titolo menzionato in questo podcast. Le opinioni e le idee espresse al momento della registrazione di questo podcast non riflettono necessariamente le opinioni e le idee di Lyxor ETF o della sua società di appartenenza, Societe Generale, e possono variare di volta in volta.

Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).Lyxor International Asset Management (LIAM) is registered in the public register of the Netherlands Authority for the Financial Markets (Autoriteit Financiële Markten) as a manager (beheerder) of a UCITS. (FOR NL BLOG DIICLAIMER)

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting, and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures, and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest

This research contains the views, opinions, and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income, and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on